Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of LysaKare in GEP-NET Patients
NCT04524442Phase 4Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- Jan 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 4 trial of lysine + arginine in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Advanced Accelerator Applications. Started Jan 2021; status: completed.
02
Drugs
lysine + arginine
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04524442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524442.